(NewsDirect)
AmpliaTherapeutics Ltd (ASX:ATX) CEO Dr Chris Burns tells Proactive thecompany has received grant funding to undertake a researchcollaboration with Australia’s national science agency to developtopical formulations of its FAK inhibitors. Amplia will work withresearchers at CSIRO to help develop formulations that could beapplied topically to wounds and burns to aid healing and reducescarring.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.